WO1997010852A2 - Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope - Google Patents
Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope Download PDFInfo
- Publication number
- WO1997010852A2 WO1997010852A2 PCT/DE1996/001821 DE9601821W WO9710852A2 WO 1997010852 A2 WO1997010852 A2 WO 1997010852A2 DE 9601821 W DE9601821 W DE 9601821W WO 9710852 A2 WO9710852 A2 WO 9710852A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ile
- asp
- cys
- leu
- phe
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title description 18
- 230000002285 radioactive effect Effects 0.000 title description 9
- 229940124530 sulfonamide Drugs 0.000 title description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 title description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 239000003446 ligand Substances 0.000 claims abstract description 35
- 229910052713 technetium Inorganic materials 0.000 claims abstract description 13
- 229910052702 rhenium Inorganic materials 0.000 claims abstract description 7
- -1 polyalkenyloxy Chemical group 0.000 claims description 46
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 19
- 229940056501 technetium 99m Drugs 0.000 claims description 17
- 239000012217 radiopharmaceutical Substances 0.000 claims description 15
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 14
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 229910052785 arsenic Inorganic materials 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 229910052698 phosphorus Inorganic materials 0.000 claims description 9
- 125000003367 polycyclic group Chemical group 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 108010064733 Angiotensins Proteins 0.000 claims description 6
- 102000015427 Angiotensins Human genes 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 239000002416 angiotensin derivative Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 claims description 5
- 108050009340 Endothelin Proteins 0.000 claims description 5
- 102000002045 Endothelin Human genes 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 125000006241 alcohol protecting group Chemical group 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 3
- 125000005248 alkyl aryloxy group Chemical group 0.000 claims description 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 150000002191 fatty alcohols Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- DUEUCUPESSMDMI-VVKHCXNMSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 DUEUCUPESSMDMI-VVKHCXNMSA-N 0.000 claims description 2
- OERILMBTPCSYNG-MLCQCVOFSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 OERILMBTPCSYNG-MLCQCVOFSA-N 0.000 claims description 2
- QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 claims description 2
- 229940123073 Angiotensin antagonist Drugs 0.000 claims description 2
- 101710091342 Chemotactic peptide Proteins 0.000 claims description 2
- NTSBFTNRWQVBCA-IVGDYKFASA-N His-leu-asp-ile-ile-trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)[C@@H](C)CC)C1=CN=CN1 NTSBFTNRWQVBCA-IVGDYKFASA-N 0.000 claims description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 2
- 108010083387 Saralasin Proteins 0.000 claims description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims description 2
- 239000002369 angiotensin antagonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 108010002990 endothelin (16-21) Proteins 0.000 claims description 2
- PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 claims 1
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 239000003586 protic polar solvent Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 abstract description 17
- 238000010168 coupling process Methods 0.000 abstract description 17
- 238000005859 coupling reaction Methods 0.000 abstract description 17
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 abstract description 9
- 229910021645 metal ion Inorganic materials 0.000 abstract description 3
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 66
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 239000001488 sodium phosphate Substances 0.000 description 12
- 229910000162 sodium phosphate Inorganic materials 0.000 description 12
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000008139 complexing agent Substances 0.000 description 8
- 229910052711 selenium Inorganic materials 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 235000011150 stannous chloride Nutrition 0.000 description 7
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 7
- 238000001665 trituration Methods 0.000 description 7
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 150000001944 cysteine derivatives Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 4
- YVKSGVDJQXLXDV-BYPYZUCNSA-N ethyl (2r)-2-amino-3-sulfanylpropanoate Chemical compound CCOC(=O)[C@@H](N)CS YVKSGVDJQXLXDV-BYPYZUCNSA-N 0.000 description 4
- 229960001913 mecysteine Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940031005 ethyl cysteine Drugs 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FSCGLKWYHHSLST-UHFFFAOYSA-N 2-(3-sulfanylpropanoylamino)acetic acid Chemical compound OC(=O)CNC(=O)CCS FSCGLKWYHHSLST-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010058907 Tiopronin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- AXQZGSXDOXASMI-QHCPKHFHSA-N methyl (2r)-2-(ethenylsulfonylamino)-3-tritylsulfanylpropanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SC[C@@H](C(=O)OC)NS(=O)(=O)C=C)C1=CC=CC=C1 AXQZGSXDOXASMI-QHCPKHFHSA-N 0.000 description 2
- DXUZZMIANHJYIU-NRFANRHFSA-N methyl (2r)-2-amino-3-tritylsulfanylpropanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SC[C@H](N)C(=O)OC)C1=CC=CC=C1 DXUZZMIANHJYIU-NRFANRHFSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960004402 tiopronin Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- NBCQMWVGEQRMRP-JTQLQIEISA-N (2R)-2-(4-methoxy-N-methylanilino)-3-sulfanylpropanoic acid Chemical compound COC1=CC=C(C=C1)N([C@@H](CS)C(=O)O)C NBCQMWVGEQRMRP-JTQLQIEISA-N 0.000 description 1
- DLMYFMLKORXJPO-FQEVSTJZSA-N (2R)-2-amino-3-[(triphenylmethyl)thio]propanoic acid Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)(SC[C@H](N)C(O)=O)C1=CC=CC=C1 DLMYFMLKORXJPO-FQEVSTJZSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- BQHFYSWNHZMMDO-WDSKDSINSA-N (2r)-2-[2-[[(1r)-1-carboxy-2-sulfanylethyl]amino]ethylamino]-3-sulfanylpropanoic acid Chemical compound OC(=O)[C@H](CS)NCCN[C@@H](CS)C(O)=O BQHFYSWNHZMMDO-WDSKDSINSA-N 0.000 description 1
- PQPZSPJVMUCVAQ-JTQLQIEISA-N (2r)-2-azaniumyl-3-[(4-methoxyphenyl)methylsulfanyl]propanoate Chemical compound COC1=CC=C(CSC[C@H](N)C(O)=O)C=C1 PQPZSPJVMUCVAQ-JTQLQIEISA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- BPNZYADGDZPRTK-UDUYQYQQSA-N Exametazime Chemical compound O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)C(\C)=N\O BPNZYADGDZPRTK-UDUYQYQQSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 description 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
- 229950010514 misonidazole Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- GGQQANJFYSLXPI-UHFFFAOYSA-N n-methylsulfanylacetamide Chemical compound CSNC(C)=O GGQQANJFYSLXPI-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical class [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- the invention relates to new chelating agents containing sulfonamide groups, pharmaceutical compositions containing these compounds, their use in radiodiagnostics and radiotherapy, processes for producing these compounds and compositions, and conjugates of these compounds with substances which selectively accumulate in diseased tissue, in particular peptides.
- radiopharmaceuticals for diagnostic and therapeutic purposes has long been known in the field of biological and medical research.
- radiopharmaceuticals are used to represent certain structures such as the skeleton, organs or tissues.
- the diagnostic application presupposes the use of such radioactive agents, which are specific to those after application
- suitable detectors such as scintillation cameras or other suitable recording methods.
- the distribution and relative intensity of the detected radioactive agent characterizes the location of a structure in which the radioactive agent is located and can be the presence of abnormalities in structure and function, pathological
- radiopharmaceuticals can be used as therapeutic agents to irradiate certain pathological tissues or areas. Such treatment requires the production of radioactive therapeutic agents that accumulate in certain structures, tissues or organs. 4
- Ion solutions or normal plasma ions such as Ca 2 +, Na + , K + and Mg 2+ .
- radiopharmaceutical agents can contain additional agents known as stabilizers. These keep the radionuclide in a stable form until it has reacted with the ligand.
- stabilizers can include agents known as transfer or auxiliary ligands that are particularly useful in stabilizing and complexing the metal in a well-defined oxidation state until the target ligand complexes the metal via ligand exchange. Examples of this type of auxiliary ligand are
- gluconheptonic acid (including their salts) gluconheptonic acid, tartaric acid, citric acid, or other common ligands, as detailed below.
- Radionuclide is the standard
- Radiopharmaceuticals are shown by first synthesizing the ligand and then reacting it with the metal radionuclide in a suitable manner in order to form a corresponding complex in which the ligand must necessarily be present unchanged after complexation, with the exception of the splitting off of any protective groups or hydrogen ions that may be present. Removal of these groups facilitates coordination of the ligand to the metal ion and thus leads to rapid complexation.
- pertechnetate is first obtained from a nuclide generator and, using suitable reducing agents (eg SnCl2 S2O4 2 " etc.), converted to a lower oxidation level, which is then followed by a suitable one
- suitable reducing agents eg SnCl2 S2O4 2 " etc.
- Chelator is stabilized. Because technetium in a row Complex formation conditions implemented. If, for example, the production of a technetium-99m radiopharmaceutical is desired, the ligand produced is mixed with a pertechnetate solution with the addition of a suitable reducing agent and the corresponding technetium complex is produced under suitable reaction conditions. These complexes are then suitably administered to the patient by injection, inhalation or ingestion.
- the solutions containing the radionuclide can, as in the case of technetium-99m, be obtained from an available Mo-99 / Tc-99m nuclide generator, or can be obtained from a manufacturer, as in the case of rhenium-186.
- the complex formation reaction is carried out at suitable temperatures (e.g. 20 ° -100 ° C) within a few minutes to several hours. To ensure complete complex formation, there is a large excess (more than 100-fold excess to the metal radionuclide) of the ligand produced and a sufficient amount of
- Reducing agent required for a complete reduction of the radionuclide used Reducing agent required for a complete reduction of the radionuclide used.
- Radiopharmaceuticals are made by combining the radionuclide complex, in an amount sufficient for diagnostic or therapeutic use, with pharmacologically acceptable radiological carriers.
- This radiological carrier should have favorable properties for the application of the radiopharmaceutical in the form of an injection,
- HSA aqueous buffer solutions
- phosphate citrate, bicarbonate etc.
- sterile water physiological saline, isotonic chloride or dicarbonate 6
- Suitable complexing agents for technetium and rhenium isotopes are e.g. cyclic amines as described by Volkert et al. (Appl. Radiol. Isot. 1982, 33; 891) and Troutner et al. (J. Nucl. Med. 1980, 21; 443), but they have the disadvantage that they are often only able to bind technetium-99m in good yields from a pH> 9.
- N2 ⁇ 2 ⁇ Syst e (Pillai, M.R.A., Troutner, D.E. et al., - Inorg. Chem. 1990, 29; 1850) are in clinical use.
- Non-cyclic N4 systems such as the major disadvantage of HMPAO is their low complex stability. Because of its instability (Ballinger, JR et al., Appl. Radiat. Isot. 1991, 42; 315, Billinghurst, MW et al., Appl. Radiat. Isot. 1991, 42; 607), Tc-99m-HMPAO must be used within 30 minutes after it has been marked so that the proportion of decay products that have a different pharmacokinetics and excretion can be kept low. Such radiochemical contaminants make it difficult to identify diseases to be diagnosed. A coupling of these chelates or
- Chelating agents to other substances that accumulate selectively in foci of disease cannot be solved by simple means, so that these are generally distributed nonspecifically in the organism.
- 2S2 chelators such as e.g. Ethylene dicysteine (EC; Verbruggen, AM et al .; J. Nucl. Med. 1992, 33; 551) meet the requirement for adequate stability of the corresponding technetium-99m complex, but only form when the pH of the complexing medium is> 9 Radio diagnostics with a purity greater than 69%.
- N3S systems (Fritzburg, A.; EP-0173424 and EP-0250013) form stable technetium-99m complexes, but must be used to form a uniform radiopharmaceutical
- the efficiency of radionuclides in in vivo diagnostics as well as therapy depends on the specificity and the selectivity of the labeled chelates to the target cell. These properties can be improved by coupling the chelates to biomolecules according to the "drug targeting" principle. Antibodies, their fragments, hormones, growth factors and substrates of receptors and enzymes are suitable biomolecules.
- the British patent application GB 2,109,407 describes the use of radioactively labeled monoclonal antibodies against tumor-associated antigens for tumor diagnosis in vivo. Likewise, direct protein labels via donor groups (amino, amide, thiol, etc.) of the protein (Rhodes, BA et al., J. Nukl. Med.
- Substances have very different properties, as well as the mechanisms by which they are enriched, it is still necessary to vary the couplable chelating agent and to be able to adapt it to the physiological requirements of the coupling partner with regard to their lipophilicity, membrane permeability, etc.
- the invention is therefore based on the object of providing stable complex compounds which are coupled or capable of coupling to different selectively enriching compounds without their specificity and selectivity being significantly affected.
- this object is achieved in that new chelating agents containing bifunctional sulfonamide groups and their coupling products with specifically enriching compounds are made available.
- the invention relates to compounds of the general formula (I)
- Carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 20 carbon atoms is substituted and / or optionally interrupted by one or more heteroatoms from the series 0, N, S, P, As, Se and / or is substituted, stands,
- R 7 and R 8 are the same or different and each represents a hydrogen atom and / or a branched or unbranched C ⁇ _g alkyl radical
- R 9 represents a hydrogen atom, a branched or unbranched C 1-6 alkyl radical or a sulfur protecting group
- R 11 represents a hydrogen atom, a branched or unbranched C 1-6 alkyl radical or one
- R 12 represents a hydrogen atom, an amino protecting group or a branched or straight-chain, cyclic or polycyclic C 1 _3o-alkyl, alkenyl, polyalkenyl, alkynyl, polyalkynyl, aryl, alkylaryl or arylalkyl group, which are optionally with hydroxy , Oxy, oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 20 carbon atoms and / or optionally substituted by one or more heteroatoms from the series 0, N, S, P, As, Se is interrupted and / or substituted, M is a radioisotope of Tc or Re and L is a ligand of the general formula (II)
- R 1 , R 2 , R 3 , R 4 and R 5 are the same or different and each represents a hydrogen atom and / or a branched or unbranched C ] __g alkyl radical,
- R6 for a hydrogen atom, for a branched or unbranched C ] __g alkyl radical or a radical -CO-R 1 ( - ) , in which
- R 10 is a hydroxyl, a branched or straight-chain, cyclic or polycyclic C ⁇ __3Q alkoxy, alkenyloxy, polyalkenyloxy, alkynyloxy, polyalkynyloxy, aryloxy, alkylaryloxy or arylalkyloxy group, optionally with
- R a and Rb b are identical or different and / or represent a hydrogen atom, a branched or straight-chain, cyclic or polycyclic C ⁇ _3Q-alkyl, alkenyl, polyalkenyl, alkynyl, polyalkynyl, aryl, alkylaryl or arylalkyl radical, optionally with hydroxy, oxy, oxo, 12
- B is a radical NHR 12 or OR 13 , in which
- R 12 and R 13 have the meaning given above
- Another object of the invention relates to the new, bifunctional sulfur atom-interrupted sulfonamide ligands of the general formula (II)
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 / R 7 , R 8 , R 9 , n, and B each have the meaning given above.
- Preferred compounds of the general formula (II) are distinguished in that n and m each represent 1 and in that R 1 , R 3 , R 4 , R 5 , R 7 and R 8 are hydrogen atoms.
- Particularly preferred compounds of the general formula (II) are distinguished in that n and m each represent 1 and in that R 1 , R 3 , R 4 , R 5 , R 7 , R 8 and R 9 are hydrogen atoms and R 6 is a hydrogen atom, a branched or unbranched C] __ g alkyl radical or a radical -CO-R 10 , R 13 represents a hydrogen atom or an alcohol protecting group.
- Preferred compounds of the general formula (I) are characterized in that n and m each represent 1 and that R 1 , R 3 , R 4 , R 5 , R 7 and R 8 are hydrogen atoms.
- Particularly preferred compounds of the general formula (I) are characterized in that n and m each represent 1 and that R 1 , R 3 , R, R 5 , R 8 and R 9 are hydrogen atoms and R 6 is a hydrogen atom, one branched or unbranched C 1-6 alkyl radical or a radical -CO-R 10 , wherein
- R 10 is a hydroxyl, a branched or straight-chain C 1 _30 alkoxy group or an N (R a R b ) group, wherein
- R a and R b are the same or different and / or represent a hydrogen atom, a branched or straight-chain, C ⁇ __ 3o-alkyl radical, optionally with carboxy, aminocarbonyl, alkoxycarbonyl or amino groups with up to 20
- Carbon atoms is substituted and / or optionally interrupted and / or substituted by one or more heteroatoms from the series 0, N, S.
- angiotensins angiotensins, angiotensin analogs, angiotensin derivatives and angiotensin antagonists as well as chemotactic peptides.
- the peptides have the following sequences
- R 10 is hydroxyl, branched or straight chain
- C] __ 3o-alkoxy group or an N (R a R b ) group where R a and Rb are the same or different and / or represent a hydrogen atom, a branched or straight-chain, C 1 _3Q-alkyl radical which may be substituted with carboxy, Aminocarbonyl, alkoxycarbonyl or amino groups with up to 20 carbon atoms is substituted and / or optionally interrupted and / or substituted by one or more heteroatoms from the series 0, N, S, is.
- the invention further relates to conjugates containing a compound of the general formula (I and / or II) and nucleotides of the DNA and RNA type and which accumulate selectively in diseased tissue
- conjugates are characterized in that the substances accumulating in the diseased tissue are peptides such as endotheline, partial sequences of endothelin, endothelin analogues, endothelin derivatives,
- the present invention furthermore further relates to compounds of the general formula (II)
- R 1 , R 2 , R 3 , R 4 and R 5 are the same or different and each represents a hydrogen atom and / or a branched or unbranched C 1-6 alkyl radical,
- R 6 represents a hydrogen atom, a branched or unbranched C 1-6 alkyl radical or a radical -CO-R 10 , wherein
- R 10 is a hydroxyl, a branched or straight-chain, cyclic or polycyclic C ⁇ .30 alkoxy, alkenyloxy, polyalkenyloxy, alkynyloxy, polyalkynyloxy, aryloxy, alkylaryloxy or arylalkyloxy group, which may optionally be combined with hydroxyl, Ala-Ser-Ala-Ser-Ser-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr- Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,
- R 12 represents a hydrogen atom, an amino protecting group or a branched or straight-chain, cyclic or polycyclic C ⁇ _3o-alkyl, alkenyl, polyalkenyl, alkynyl, polyalkynyl, aryl, alkylaryl or arylalkyl group, which optionally with hydroxy, oxy , Oxo, carboxy, aminocarbonyl, alkoxycarbonyl, amino, aldehyde or alkoxy groups with up to 20 carbon atoms and / or optionally substituted by one or more heteroatoms from the series O, N, S, P, As, Se is interrupted and / or substituted,
- R 13 represents a hydrogen atom or an alcohol protecting group
- Substances containing carboxyl or amino groups such as naturally occurring or modified oligonucleotides, in which the degradation is prevented or made more difficult by naturally occurring nucleases, peptides, proteins, antibodies or their fragments amidically or, in the case of substances containing hydroxyl groups, such as fatty alcohols, ester-like or in the case of aldehyde groups containing substances is imidic
- the compounds of the general formula (II) according to the invention are prepared by adding 2-chloroethanesulfonic acid chloride optionally substituted with R 3 and R 4 in a manner known per se in an aprotic solvent with addition of a Oxy-, oxo-,
- Amino, aldehyde or alkoxy groups with up to 20 carbon atoms is substituted and / or optionally interrupted and / or substituted by one or more heteroatoms from the series 0, N, S, P, As, Se,
- R 7 and R 8 are the same or different and each represents a hydrogen atom and / or a branched or unbranched C ⁇ _g alkyl radical
- R 9 represents a hydrogen atom, a branched or unbranched C 1-6 alkyl radical or a sulfur protecting group
- R! 1 for a hydrogen atom, for a branched or unbranched C ⁇ _g alkyl radical or for one
- Sulfur protection group stands, 20th
- kits which are used to produce radiopharmaceuticals, consisting of a compound of the general formula (II) or a conjugate according to the invention containing compounds of the general formula (I and / or II) and substances which accumulate selectively in tissues, a Reducing agents and optionally an auxiliary ligand, which are in the dry state or in solution, as well as instructions for use with a reaction instruction for reacting the described compounds with technetium-99m or Re in the form of a pertechnetate solution or perrhenate solution.
- the invention also relates to a radiopharmaceutical composition for the non-invasive in vivo presentation of organs, receptors and receptor-containing tissue and / or of atherosclerotic plaques, which contain a compound of the general formula (I) or a conjugate according to the invention containing compounds of the general formula (I and / or II) and contains substances which accumulate selectively in tissues, if appropriate with the additives customary in galenics, the compound being prepared in a kit with technetium-99m or Re in the form of a pertechnetate or perrhenate solution.
- R 5 , R 6 , R 7 , R 8 , R 9 and m have the meaning given above,
- R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and m have the meaning given above,
- auxiliary bases can, for example, tertiary amines, alkali and
- Alkaline earth hydroxides, alkali and alkaline earth carbonates are Alkaline earth hydroxides, alkali and alkaline earth carbonates.
- Sulfur protecting groups are established or split off using methods known to the person skilled in the art.
- the coupling to substances which accumulate selectively in diseased tissues also takes place according to methods known per se to the person skilled in the art (for example Fritzberg et al.; J. Nucl. Med. 26, 7 (1987)), for example by reacting electrophilic groups of the complex ligand with nuceophilic ones Centers of substances selectively accumulating in diseased tissues or by reaction of nucleophilic groups of the chelator with electrophilic groups of substances selectively accumulating in diseased tissues.
- the coupling partners include different biomolecules used. So e.g. Ligands that bind to specific receptors and thus show changes in receptor density, these include Peptides,
- tumor cells have an altered density of receptors for peptide hormones or growth factors, e.g. the "epidermal growth factor” (EgF).
- EgF epidermal growth factor
- concentration differences can be used for the selective enrichment of cytostatics in tumor cells (E. Abound-Pirak et al.; Proc.Natl.Acad.Sci. USA 86: 3778 1989).
- Other biomolecules are metabolites that can be introduced into the metabolism of the cells and indicate a changed metabolism; these include e.g. Fatty acids,
- the radiopharmaceutical composition is administered to a patient in an amount of 0.1 to 30 mCi, preferably 0.5 to 10 mCi per 70 kg of body weight, and the radiation emitted by the patient is recorded.
- the ligands according to the invention and their coupling products can be labeled on substances which accumulate selectively in diseased tissues at room temperature and at a physiological pH.
- suitable protective groups which can be split off with different reaction conditions depending on the coupling product, always ensures that undesired side reactions cannot occur during the purification of the coupling products. This ensures that no undesired crosslinking reactions or oxidation of free sulfhydryl groups to form disulfides
- compositions according to the invention are prepared in a manner known per se by adding the complexing agents according to the invention with the addition of a reducing agent, preferably tin (II) salts such as chloride, pyrophosphate or tartrate - and optionally with the addition of galenics usual additives - dissolves in aqueous medium and then sterile filtered.
- a reducing agent preferably tin (II) salts such as chloride, pyrophosphate or tartrate -
- galenics usual additives usual additives - dissolves in aqueous medium and then sterile filtered.
- Suitable additives are, for example, physiologically harmless buffers (e.g. tromethamine), small additions of electrolytes (e.g. sodium chloride), stabilizers (e.g. gluconate, phosphates or phosphonates).
- the pharmaceutical composition according to the invention is in the form of a solution or in lyophilized form and is added shortly before application with a solution of Tc-99m pertechnetate, eluted from commercially available Mo / Tc generators, or a perrhenate solution.
- the pharmaceutical compositions according to the invention are dosed in amounts of 1x10 " 5 to 5xl0 4 nmol / kg body weight, preferably in amounts between 1x10 " 3 to 5xl0 2 nmol / kg body weight.
- the amount of radioactivity for diagnostic applications is between 0.05 to 50 mCi, preferably 5 to
- Other metabolic products such as saccharides, deoxyglucose, lactate and amino acids (leucine, methyl methionine, glycine) were modified with the help of the PET technique for imaging
- Antibodies or their fragments, polysaccharides such as dextrans or starches, bleomycins, hormones, enzymes, polypeptides such as polylysine and nucleotides of the DNA or RNA type are possible.
- Coupling products of the chelates according to the invention or their complexes with technetium-99m or Re with endothelines, endothelin derivatives or with partial sequences of the endotheline or their derivatives for the detection of atherosclerotic vascular diseases have proven particularly favorable. These derivatives were applied to WHHL rabbits which, due to a genetic defect in the LDL receptor, have high LDL concentrations in the blood and thus have atherosclerotic lesions.
- a solution of 3.59 g of vinyl sulfonic acid 2. (10 mmol) and 2 g triethylamine in 25 ml dichloromethane is cooled to 0 ° C. Then 1.05 g of N-methylmercaptoacetamide are added in a little dichloromethane and at RT 24
- N-vinylsulfonyl-S- (4-methoxybenzyl) cysteine ethyl ester (2) An ice-cooled solution of 3.06 g (10 mmol) of the S-protected cysteine derivative 1 and 1.79 g of chloroethanesulfonyl chloride (11 mmol) in 10 ml dichloromethane dry pyridine (44 mmol) is slowly added while cooling with ice. The mixture is allowed to warm to RT and, after the reaction has ended, 20 ml of dilute HCl are added and the dichloromethane phase is separated off. The aqueous phase is extracted several times with dichloromethane, washed with water, dried, concentrated and chroographed 28
- 50 ul of this ligand solution are mixed with 100 ul ethanol, 150 ul phosphate buffer pH 8.5, 50 ul of a deoxygenated aqueous citrate solution (50 mg / ml), 2.5 ul of a deoxygenated tin (II) chloride solution (5 mg / ml 0.1 N HCl) and 100 ⁇ l of a pertechnetate solution (400-1000 ⁇ Ci) are added.
- reaction mixture is examined for the purity of the Tc complex formed by means of HPLC: LiChrospher RP-18 column, 5 ⁇ , 125 ⁇ 4.6 mm; Gradient elution from 100% A to 100% B within 15 min (eluent A: acetonitrile / sodium phosphate 5 mM, pH 2.0 (10/90); eluent B: acetonitrile / sodium phosphate 5 mM, pH 2.0 (75/25);
- the reaction mixture is examined for the purity of the Tc complex formed by means of HPLC: LiChrospher RP-18 column, 5 ⁇ , 125 ⁇ 4.6 mm; Gradient elution from 100% A to 100% B within 15 min (eluent A: acetonitrile / sodium phosphate 5 mM, pH 2.0 (10/90); eluent B: acetonitrile / sodium phosphate 5 mM, pH 2.0 (75/25); 1 ml / min.
- the radiochemical purity is> 96%.
- N- ⁇ 4-Carboxy-3-thiabutylsulfonvl ⁇ cysteine ethyl ester (13) 558 mg of the protected S-compound 12 (1 mmol) and a trace of anisole are added to 10 ml of trifluoroacetic acid at RT and a trace of anisole is added and the mixture is stirred at 50 ° C. for 2 hours. After finished
- the trifluoroacetic acid is removed in vacuo, the residue is taken up in ethyl acetate, washed with saturated sodium chloride solution, dried and concentrated. The oily residue is crystallized by trituration with diethyl ether.
- 50 ul of this ligand solution are mixed with 100 ul ethanol, 150 ul phosphate buffer pH 8.5, 50 ul of a deoxygenated aqueous citrate solution (50 mg / ml), 2.5 ul of a deoxygenated tin (II) chloride solution (5 mg / ml 0.1 N HCl) and 100 ⁇ l of a pertechnetate solution (400-1000 ⁇ Ci) are added.
- the reaction mixture is examined for the purity of the Tc complex formed by means of HPLC: LiChrospher RP-18 column, 5 ⁇ , 125 ⁇ 4.6 mm; Gradient elution from 100% A to 100% B within 15 min (eluent A: acetonitrile / sodium phosphate 5 mM, pH 2.0 (10/90); eluent B.- acetonitrile / sodium phosphate 5 mM, pH 2, 0 (75/25); lml / min.
- the radiochemical purity is> 95%. 34
- 50 ⁇ l of this ligand solution are mixed with 100 ⁇ l ethanol, 150 ul phosphate buffer pH 8, 5, 50 ul of a deoxygenated aqueous citrate solution (50 mg / ml), 2.5 ul of a deoxygenated tin (II) chloride solution (5 mg / ml 0.1 N HCl) and 100 ul one Pertechnetate solution (400-1000 ⁇ Ci) added.
- the reaction mixture is after a
- a solution of 1.18 g of H2N-Arg-Val-Tyr-Ile-His-Por-Phe-His-Leu-COOH (1 mmol) in DMF is then added dropwise within 30 minutes. It will be first 150 ul phosphate buffer pH 8, 5, 50 ul of a deoxygenated aqueous citrate solution (50 mg / ml), 2.5 ul of a deoxygenated tin (II) chloride solution (5 mg / ml 0.1 N HCl) and 100 ul one Pertechnetate solution (400-1000 ⁇ Ci) added. The reaction mixture is after a
- N-vinylsulfonyl-S-trityl-cysteine methyl ester An ice-cooled solution of 8.28 g (20 mmol) of the S-trityl cysteine derivative 12th and 4.89 g of chloroethanesulfonyl chloride (30 mmol) in 50 ml of dichloromethane is slowly added
- R 7 and R 8 are the same or different and each represents a hydrogen atom and / or a branched or unbranched C ⁇ _g alkyl radical
- R 9 represents a hydrogen atom, a branched or unbranched C 1-6 alkyl radical or a sulfur protecting group
- R 11 represents a hydrogen atom, a branched or unbranched C 1-6 alkyl radical or a sulfur protecting group
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96945139A EP0853488A2 (de) | 1995-09-21 | 1996-09-19 | Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope |
AU14359/97A AU1435997A (en) | 1995-09-21 | 1996-09-19 | Xsns-type bi-functional sulphide-containing sulphonamide chelating agents for radioactive isotopes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19536781.2 | 1995-09-21 | ||
DE1995136781 DE19536781A1 (de) | 1995-09-21 | 1995-09-21 | Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997010852A2 true WO1997010852A2 (de) | 1997-03-27 |
WO1997010852A3 WO1997010852A3 (de) | 1997-08-28 |
Family
ID=7773888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1996/001821 WO1997010852A2 (de) | 1995-09-21 | 1996-09-19 | Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0853488A2 (de) |
AU (1) | AU1435997A (de) |
CA (1) | CA2232391A1 (de) |
DE (1) | DE19536781A1 (de) |
WO (1) | WO1997010852A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024482A2 (de) * | 1996-12-04 | 1998-06-11 | Schering Aktiengesellschaft | Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung |
WO2002070018A3 (en) * | 2001-03-02 | 2002-12-05 | Amersham Plc | Tetradentate peptide-chelate conjugates for colorectal cancer diagnosis |
WO2005044313A2 (en) * | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0946202B1 (de) * | 1996-10-28 | 2003-09-10 | Amersham Health AS | Kontrastmittel |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
BR9909420A (pt) | 1998-03-31 | 2001-09-25 | Du Pont Pharm Co | Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
CN1356913A (zh) | 1998-12-18 | 2002-07-03 | 杜邦药品公司 | 玻连蛋白受体拮抗剂药物 |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP1140864A2 (de) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Pharmazeutische zusammensetzungen, vitronectinrezeptor antagonisten enthaltend |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022493A1 (de) * | 1993-03-31 | 1994-10-13 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Chelatbildner vom typ xn1s1x' für radioaktive isotope, deren metallkomplexe und ihre verwendung in diagnostik und therapie |
WO1995003280A1 (en) * | 1993-07-19 | 1995-02-02 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
WO1995005398A1 (en) * | 1993-08-17 | 1995-02-23 | Neorx Corporation | S3n chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins |
-
1995
- 1995-09-21 DE DE1995136781 patent/DE19536781A1/de not_active Withdrawn
-
1996
- 1996-09-19 WO PCT/DE1996/001821 patent/WO1997010852A2/de not_active Application Discontinuation
- 1996-09-19 AU AU14359/97A patent/AU1435997A/en not_active Abandoned
- 1996-09-19 EP EP96945139A patent/EP0853488A2/de not_active Withdrawn
- 1996-09-19 CA CA 2232391 patent/CA2232391A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022493A1 (de) * | 1993-03-31 | 1994-10-13 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Chelatbildner vom typ xn1s1x' für radioaktive isotope, deren metallkomplexe und ihre verwendung in diagnostik und therapie |
WO1995003280A1 (en) * | 1993-07-19 | 1995-02-02 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
WO1995005398A1 (en) * | 1993-08-17 | 1995-02-23 | Neorx Corporation | S3n chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins |
Non-Patent Citations (2)
Title |
---|
BIOCONJUGATE CHEMISTRY, Bd. 1, Nr. 2, 1.Januar 1990, Seiten 132-137, XP000371813 KWAMENA E BAIDOO ET AL: "SYNTHESIS OF A DIAMINEDITHIOL BIFUNCTIONAL CHELATING AGENT FOR INCORPORATION OF TECHNETIUM-99M INTO BIOMOLECULES" * |
NUCL MED BIOL, FEB 1995, VOL. 22, NO. 2, PAGES 165-73, XP002034516 ANDERSON CJ ET AL: "N,N'-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies." * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024482A2 (de) * | 1996-12-04 | 1998-06-11 | Schering Aktiengesellschaft | Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung |
WO1998024482A3 (de) * | 1996-12-04 | 1999-04-01 | Schering Ag | Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung |
WO2002070018A3 (en) * | 2001-03-02 | 2002-12-05 | Amersham Plc | Tetradentate peptide-chelate conjugates for colorectal cancer diagnosis |
US7608242B2 (en) | 2001-03-02 | 2009-10-27 | Ge Healthcare Limited | Peptide-chelate conjugates |
WO2005044313A2 (en) * | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
WO2005044313A3 (en) * | 2003-11-06 | 2006-05-11 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
JP2007510643A (ja) * | 2003-11-06 | 2007-04-26 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 医薬化合物 |
US7785566B2 (en) | 2003-11-06 | 2010-08-31 | Ge Healthcare, Inc. | Pharmaceutical compounds |
Also Published As
Publication number | Publication date |
---|---|
CA2232391A1 (en) | 1997-03-27 |
EP0853488A2 (de) | 1998-07-22 |
AU1435997A (en) | 1997-04-09 |
WO1997010852A3 (de) | 1997-08-28 |
DE19536781A1 (de) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0417870B1 (de) | Chelatbildner zur Komplexierung von radioaktiven Isotopen, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie | |
DE69837038T2 (de) | Tetraaza- oder n2s2-komplexanten, und deren verwendung in der radiodiagnostik oder radiotherapie | |
EP0692976B1 (de) | Chelatbildner vom typ xn 1?s 1?o 1? für radioaktive isotope, deren metallkomplexe und ihre verwendung in diagnostik und therapie | |
EP0853488A2 (de) | Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsns für radioaktive isotope | |
WO1997010853A2 (de) | Bifunktionelle nicotinamid-chelatbildner vom typ n2s2 für radioaktive isotope | |
EP0851770A2 (de) | Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ s?2 ny für radioaktive isotope | |
EP0692979A1 (de) | Bifunktionelle chelatbildner und ihre anwendung in der radiopharmazeutik | |
EP0692981B1 (de) | Chelatbildner vom typ xn 1?s 1?x' für radioaktive isotope, deren metallkomplexe und ihre verwendung in diagnostik und therapie | |
DE19860289C2 (de) | Neue Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium | |
EP0502594A1 (de) | Chelate, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie | |
EP0692980B1 (de) | Chelatbildner vom typ s3n2 für radioaktive isotope, deren metallkomplexe und ihre verwendung in diagnostik und therapie | |
EP0851847A2 (de) | Bifunktionelle sulfidhaltige sulfonamid-chelatbildner vom typ xsny für radioaktive isotope | |
DE69023616T2 (de) | Radionukleid-chelatverbindungen zur radiomarkierung von proteinen. | |
DE4425781A1 (de) | Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel | |
WO1995012610A1 (de) | N-alkyl-peptidchelatbildner, deren metallkomplexe mit radionukliden, verfahren zu ihrer herstellung und diese verbindungen enthaltende radiopharmazeutische zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA HU JP KR NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA HU JP KR NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996945139 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref country code: CA Ref document number: 2232391 Kind code of ref document: A Format of ref document f/p: F Ref document number: 2232391 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1996945139 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996945139 Country of ref document: EP |